2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; [Internet] American Association for the Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: [Último acceso 25 diciembre 2013 ]2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. Vol. 54, 2011, pp.1433-44.Disponible en: http://www.aasld.org/practiceguidelines/Documents/AASLDUpdateTreatmentGenotype1HCV11113.pdf Accessed November 24, 2013.
3. Hézode C, Fontaine H, Dorival C; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) — NCT01514890. J Hepatol2013; 49; 434-41.
4. Sulkowski MS, Cooper C, Hunyady B. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol2011; 8; 212-23.
5. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol2013; 13; 535-42.
6. Lewis R. [Intenet] Hepatitis C: 6 Prevention Strategies That Work. [Último acceso 19 diciembre 2013]. Medscape. 2013. Disponible en; http://www.medscape.com/viewarticle/808539.
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009; 46; (4) ;1335-74.
8. Greg Fitz, MD. Promising New Era in Hepatitis C Treatment. The Liver Meeting: American Association for the Study of Liver Diseases (AASLD), Washington DC, November 11. 2013
9. Lawitz E, Lalezari JP, Hassanein T. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis2013; 13; 401-8.
10. Liver Center of Excellence at the Digestive Disease; Institute at the Virginia Mason Medical Center in Seattle, Washington, Hepatitis C Drug Sofosbuvir Still Effective at 24 Weeks. American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting and Postgraduate Course. American College of Gastroenterology (ACG), Annual Scientific Meeting and Postgraduate Course: San Diego, California, 2013 Abstract 38.
11. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet2013; 381; 2100-7.
13. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368; 1878-87.
14. Lawitz E, Ghalib R, Rodriguez-Torres M. COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, Georgia. March 3-6, 2013; Abstract 155LB.
15. Jacobson IM, Gordon SC, Kowdley KV. POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med2013; 368; 1867-77.
16. Poordad F, Lawitz E, Kowdley KV. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med2013; 386; 45-53.
17. Lawitz E, Poordad F, Pang PS. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2013 Nov 1. [ Proxima aparición]
18. Lawitz EJ, Gruener D, Hill JM. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 0l; (57); 24-31.
20. Cheng G, Peng B, Corsa A. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885. J Hepatol 2012, 56, Pp. (Suppl 2):S464.
21. Zeuzem S, Dusheiko GM, Salupere R. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. In: Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC. Abstract 1085.
22. Jacobson I, Ghalib RH, Rodriguez-Torres M. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC. Abstract LB-3.
23. Gane EJ, Stedman CA, Hyland RH. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin: the ELECTRON trial. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC; November 1-5, 2013. Abstract 21.
24. Sulkowski MS, Rodriguez-Torres M, Lalezari JP. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC; November 1-5, 2013. Abstract 212.
25. Cure S, Guerra I, Dusheiko G. Long-term outcomes of sofosbuvir (SOF) for the treatment of chronic hepatitis C infected (CHC) patients. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC; November 1-5, 2013. Abstract 1107.
26. Charlton MR, Gane EJ, Manns MP, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC; November 1-5, 2013. Abstract LB-2.
27. Curry R, Forns X, Chung RT, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Program and abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC; November 1-5, 2013. Abstract 213.